Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FLT3
REST API REST API
Homo sapiens
FLT3 is differentially expressed in 186 experiments: 63 organism parts: cerebellum, blood, ... (61 more);, 78 disease states: normal, acute myeloid leukemia, ... (76 more);, 66 cell types 117 cell lines 24 compound treatments and 74 other conditions.
Synonyms CD135, FLK2, STK1
Orthologs F1P380_CHICK (Gallus gallus)   flt3 (Danio rerio)   Flt3 (Mus musculus)   F1MRU0_BOVIN (Bos taurus)   Flt3 (Rattus norvegicus)   Pvr (Drosophila melanogaster)   FLT3 (Xenopus laevis)   NP_001018647.1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term endoplasmic reticulum, protein binding, cytokine-mediated signaling pathway, negative regulation of cell proliferation, positive regulation of cell proliferation, membrane, peptidyl-tyrosine phosphorylation, protein tyrosine kinase activity, positive regulation of MAP kinase activity, transmembrane receptor protein tyrosine kinase signaling pathway, hemopoiesis, ATP binding, transferase activity, transferring phosphorus-containing groups, integral to plasma membrane, receptor activity, nucleotide binding, protein serine/threonine kinase activity, transmembrane receptor protein tyrosine kinase activity, protein homodimerization activity, integral to membrane, cell surface, endoplasmic reticulum lumen, cytokine receptor activity, protein kinase activity, regulation of apoptosis, pro-B cell differentiation, negative regulation of B cell differentiation, myeloid progenitor cell differentiation, lymphocyte differentiation, lymphoid progenitor cell differentiation, positive regulation of tyrosine phosphorylation of STAT protein, pro-T cell differentiation, vascular endothelial growth factor receptor signaling pathway, positive regulation of MAPKKK cascade, protein autophosphorylation, protein phosphorylation, cellular response to cytokine stimulus, positive regulation of phosphatidylinositol 3-kinase activity, phosphatidylinositol 3-kinase binding, positive regulation of phosphatidylinositol 3-kinase cascade, vascular endothelial growth factor-activated receptor activity
InterPro Term Immunoglobulin, Prot_kinase_cat_dom, Ig-like, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Tyr_kinase_CSF1/PDGF_rcpt, Se/Thr_kinase-like_dom
UniProt Accession Q5VTU6, P36888, E7ER61
Gene-Disease Assocation LEUKEMIA, ACUTE MYELOID; AML
Search EB-eye ENSG00000122025
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-MTAB-24, E-MTAB-25, E-GEOD-7540, ... (20 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, E-GEOD-24147, E-MTAB-62, ... (20 experiments)

Factor Value U/D Experiments
ARH77
1
E-MTAB-37
HPAC
1
E-MTAB-37
JVM3
1
E-MTAB-37
SW982
1
E-MTAB-37
RKO
1
E-MTAB-62
L428
1
E-MTAB-37
111 more value(s).


Cell type

studied in E-MEXP-1242, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-20677, ... (35 experiments)

Factor Value U/D Experiments
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
CD105+ endothelial
1
E-AFMX-5
activated B-cell
1
E-MEXP-2360
leydig cell
1
E-MTAB-25
undifferentiated cell
1
E-GEOD-21668
60 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-25, E-GEOD-1577, E-MEXP-2069, E-GEOD-22148, ... (39 experiments)

Factor Value U/D Experiments
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-1729
chronic myelogenous leukemia
2
E-MTAB-62, E-GEOD-5550
control
1
2
E-GEOD-16363, E-GEOD-8121, E-GEOD-20602
colorectal adenocarcinoma
1
E-MTAB-62
endometriosis
1
E-GEOD-7307
gulf war illness
1
E-MEXP-2069
72 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-15205, E-TABM-782, E-GEOD-5824, E-TABM-868, ... (17 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
M-CSF
1
E-GEOD-5099
NaOH
1
E-MEXP-2590
mercaptopurine, methotrexate
1
E-GEOD-412
Cxcl12
1
E-GEOD-7307
TNF
1
E-GEOD-15205
18 more value(s).


Biosource provider

studied in E-TABM-325, E-MTAB-37

Factor Value U/D Experiments
ATCC
1
E-MTAB-37
DMSZ
1
E-MTAB-37
Discordant twin
1
E-TABM-325
ECACC
1
E-MTAB-37
StThomas twins
1
E-TABM-325


BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21589, E-GEOD-16363, E-GEOD-19665 ... (5 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-MTAB-62

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease free interval dfi in months
studied in E-GEOD-22541

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-22148, E-TABM-147, E-GEOD-21138, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-GEOD-7578

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-17476, E-GEOD-22593, E-TABM-321, ... (8 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1446, E-GEOD-22278, E-MEXP-2146, E-GEOD-20505

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MEXP-2069, E-GEOD-19330, E-GEOD-19519, E-GEOD-6919, ... (20 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-980

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

No of metastases
studied in E-GEOD-22541

No of pulmonary metastases
studied in E-GEOD-22541

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-7114

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254

Replicate
studied in E-GEOD-18791

RNAi
studied in E-MEXP-1509, E-GEOD-3697, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70

Sex
studied in E-GEOD-19743, E-GEOD-16363

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Tissue
studied in E-GEOD-30573

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-21909

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-TABM-43, E-GEOD-1561, E-GEOD-4922

Processing time: 0.311 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM